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Abstract
Neoplastic cell traffic abnormalities are central to the pathogenesis of chronic lymphocytic leukemia (CLL). Enhanced CXC
chemokine receptor-4 (CXCR4) and chemokine receptor-7 (CCR7) recycling contributes to the elevated surface levels of
these receptors on CLL cells. Here we have addressed the role of p66Shc, a member of the Shc family of protein adaptors the
expression of which is defective in CLL cells, in CXCR4/CCR7 recycling. p66Shc reconstitution in CLL cells reduced
CXCR4/CCR7 recycling, lowering their surface levels and attenuating B-cell chemotaxis, due to their accumulation in Rab5
+ endosomes as serine-phosphoproteins bound to β-arrestin. This results from the ability of p66Shc to inhibit Ca2+ and
PP2B-dependent CXCR4/CCR7 dephosphorylation and β-arrestin release. We also show that ibrutinib, a Btk inhibitor that
promotes leukemic cell mobilization from lymphoid organs, reverses the CXCR4/CCR7 recycling abnormalities in CLL
cells by increasing p66Shc expression. These results, identifying p66Shc as a regulator of CXCR4/CCR7 recycling in B
cells, underscore the relevance of its deficiency to CLL pathogenesis and provide new clues to the mechanisms underlying
the therapeutic effects of ibrutinib.
Introduction
The stromal microenvironment has emerged as a major
player in the survival and expansion of neoplastic cells in
chronic lymphocytic leukemia (CLL), a hematological
neoplasm characterized by the progressive accumulation of
mature CD5+ B cells in blood, bone marrow (BM) and
secondary lymphoid organs (SLOs) [1–3]. B lymphocyte
homing to SLOs and BM is regulated by the chemokine
receptors chemokine receptor-7 (CCR7) and CXC chemo-
kine receptor-4 (CXCR4), respectively, which respond to
stroma-derived ligands [4–8]. This activity is counteracted
by sphingosine-1-phosphate (S1P) receptors that promote
lymphocyte egress from their homing sites toward the S1P-
rich circulatory fluids [9]. CLL cells display abnormally
high levels of surface CXCR4 and CCR7 [10–12] con-
comitant with a defect in sphingosine-1-phosphate receptor
1 (S1PR1) expression [13], resulting in an altered balance
between entry and egress signals that might prolong leu-
kemic cell residency in the pro-survival stromal niche.
The magnitude and duration of the cellular response to
chemokines are regulated by receptor desensitization/
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resensitization, similar to other G-protein-coupled receptors
(GPCR). Following serine/threonine phosphorylation and β-
arrestin binding, GPCRs are internalized and targeted to
Rab5+ (Ras-related in brain 5) endosomes, wherefrom on
dephosphorylation they recycle to the plasma membrane or
are alternatively routed to lysosomes for degradation [14–
L. Patrussi et al.
18]. The mechanism underlying this key dephosphorylation
step on CXCR4 and CCR7 is currently unknown. CXCR4
and CCR7 recycling is potentiated in CLL cells, which
contributes to their increased surface levels [11], under-
scoring the importance of characterizing this pathway.
We have implicated a defect of p66Shc, a proapoptotic
Shc family member, in CLL pathogenesis [19]. The
impairment in p66Shc expression contributes to the apop-
tosis defects of CLL cells due to its ability to modulate Bcl-
2 family gene expression [19]. This extends to the genes
encoding CCR7 and S1PR1, implicating p66Shc deficiency
both in the upregulation of CCR7 expression and in the
downmodulation of S1PR1 in CLL cells [13]. Furthermore,
p66Shc suppresses CXCR4 and CXCR5 signaling in B cells
[20]. Hence the p66Shc expression defect may impact at
multiple levels on CLL cell trafficking to promote their
accumulation in the stromal niche.
Here we asked whether p66Shc is implicated in
homing receptor recycling. We show that p66Shc is a
negative regulator of CXCR4/CCR7 recycling in B cells
and that their enhanced recycling in CLL cells is corrected
by restoring p66Shc expression. We show that
p66Shc limits CXCR4/CCR7 recycling by inhibiting their
Ca2+ and phosphatase type 2B (PP2B)-dependent
dephosphorylation, on which their release from β-arrestin
and transit to recycling endosomes was found to
crucially depend. Furthermore, we provide evidence that
ibrutinib, a Bruton tyrosine kinase (Btk) inhibitor used in
combination therapies for CLL, normalizes the surface
levels and subcellular distribution of CXCR4/CCR7 by
limiting their recycling via an increase in p66Shc
expression.
Results
p66Shc negatively regulates CXCR4 and CCR7
recycling in B cells
Based on its ability to attenuate CXCR4 and
CXCR5 signaling [20], we investigated the role of p66Shc
in recycling of CXCR4 and the related homing receptor
CCR7, using as model the CLL-derived MEC B-cell line,
which does not express p66Shc [13], stably transfected with
p66Shc-encoding (p66) or empty (ctr) vector. Ligand-
dependent recycling of internalized CXCR4/CCR7 in cells
treated with either the respective antibodies (Fig. 1a; Sup-
plementary Figure 1a) or chemokine ligands (Supplemen-
tary Figure 1b) was profoundly impaired in the presence of
p66Shc, resulting in lower surface CXCR4/CCR7 (Fig. 1b).
Ligand-independent CXCR4/CCR7 recycling was also
impaired in p66Shc-expressing cells (Supplementary Figure
1c). Similar results were obtained when recycling and sur-
face CXCR4/CCR7 were analyzed in splenic B cells from
p66Shc-/- mice or wild-type mice, where p66Shc is
expressed at physiological levels (Figs. 1c, d). A time
course analysis of antibody-induced CXCR4/CCR7 down-
modulation showed that p66Shc affected neither the kinetics
or the extent of receptor downmodulation (Supplementary
Figure 1d). Hence, p66Shc acts as a negative regulator of
CXCR4 and CCR7 recycling downstream of their ligand-
dependent internalization.
A substantial proportion of CXCR4/CCR7 is stored in
recycling endosomes in B cells [11]. We asked whether
p66Shc may alter the quantitative balance between surface
and vesicular CXCR4/CCR7 by interfering with their
recycling. CXCR4/CCR7 were quantitated by flow cyto-
metry in the intact and permeabilized MEC B-cell trans-
fectants, as well as on splenic B cells from wild-type and
p66Shc-/- mice. Surface CXCR4/CCR7 was lower in the
presence of p66Shc with a concomitant increase in the
intracellular pool (Supplementary Figure 2a and b), result-
ing in a lower ratio of surface-to-total receptor in p66Shc-
expressing cells (Figs. 1e, f). Hence, p66Shc affects the
subcellular distribution of both receptors, favoring their
association with the endosomal pool.
Fig. 1 p66Shc negatively regulates CXCR4 and CCR7 recycling in B
cells. a, c Flow cytometric analysis of CXCR4/CCR7 recycling in
MEC B cells stably transfected with empty vector (ctr) or with a vector
encoding p66Shc (p66) a, or in splenic B cells purified from wild-type
(p66+/+) or p66Shc-/- (p66-/-) mice c. Data are presented as % of
internalized receptors that have recycled to the cell surface at the
indicated times and refer to duplicate samples from four independent
experiments a or to duplicate samples from eight p66Shc+/+ and eight
p66Shc-/- mice c. The immunoblot analysis with anti-Shc antibodies of
postnuclear supernatants from ctr and p66 MEC B cells a or from
purified splenic B cells from p66Shc+/+ and p66Shc-/- mice c are
shown on the top of the respective panels. b, d Flow cytometric
analysis of CXCR4/CCR7 surface staining in ctr and p66 MEC B cells
(b, n= 4) or in splenic B cells from eight p66Shc+/+ and eight
p66Shc-/- mice d. e, f Ratio of surface-to-total MFI of CXCR4 and
CCR7 in ctr and p66 MEC B cells (e, n= 4), or in splenic B cells
purified from p66Shc+/+ or p66Shc-/- mice (f, duplicate samples from
eight wild-type and eight p66Shc-/- mice). Data are expressed as ratio
(mean±SD) of MFI in non-permeabilized cells (surface) to permea-
bilized (total) cells. g Flow cytometric analysis of CXCR4/CCR7
recycling in purified M-CLL (n= 11) or U-CLL (n= 8) B cells
nucleofected with either empty vector (ctr) or an expression construct
encoding p66Shc (p66). Data are presented as % of internalized
receptors that have recycled to the cell surface at the indicated times
and refer to duplicate samples for each patient. The immunoblot
analysis with anti-Shc and anti-actin antibodies of postnuclear super-
natants from the CLL transfectants is shown above. h Flow cytometric
analysis of CXCR4/CCR7 surface staining in purified M-CLL (n= 12)
or U-CLL (n= 12) B cells nucleofected as above. i Ratio of surface-to-
total MFI of CXCR4 (left) and CCR7 (right) from M-CLL or U-CLL
ctr or p66Shc B-cell transfectants. Data are expressed as ratio (mean
±SD) of MFI in non-permeabilized cells (surface) to permeabilized
(total) cells. Error bars, SD. Student’s t-test (unpaired). ***p<0.001;
**p<0.01; *p<0.05
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p66Shc reconstitution in CLL cells normalizes the
chemokine-dependent enhancement in CXCR4/CCR7
recycling and chemotaxis
CXCR4/CCR7 recycling, as well as ligand-dependent che-
motaxis are strongly enhanced in CLL cells, especially in
patients with unmutated immunoglobulin Heavy chain
variable locus (IGHV) [11]. To assess whether the p66Shc
defect in CLL cells [19] accounts for these recycling
abnormalities, we measured CXCR4/CCR7 recycling in
leukemic cells reconstituted with p66Shc (Fig. 1g). Patients
were grouped according to IGHV mutational status (muta-
ted, M-CLL; unmutated, U-CLL). Forced p66Shc expres-
sion resulted in a striking decrease in CXCR4/CCR7
recycling in both patient subgroups (Fig. 1g), which led to a
reduction in surface CXCR4/CCR7 (Fig. 1h), implicating
the p66Shc expression defect in the enhanced ability of
CLL cells to recycle these receptors. p66Shc reconstitution
in CLL cells also led to a modification in the subcellular
distribution of CXCR4/CCR7, with a greater proportion of
receptors localized intracellularly to the expense of the
plasma membrane (Supplementary Figure 2c), resulting in a
lower ratio of surface-to-total receptor (Fig. 1i). Consistent
with our previous reports [11, 19], p66Shc reconstitution in
CLL cells resulted in a decrease in the mRNA and overall
protein levels of CCR7 but did not affect the levels of
CXCR4 (Supplementary Figure 3a and b). Hence, although
the decreased amount of surface CCR7 in p66Shc-
expressing B cells is partly related to decreased expres-
sion, this does not apply to CXCR4, whose decrease is
mainly accounted for by reduced recycling.
Concomitant with the recycling-related reduction in
surface CXCR4/CCR7 (Supplementary Figure 2C), p66Shc
reconstitution in B cells from M-CLL and U-CLL patients
resulted in a strong inhibition of CXCL12-/CCL21-depen-
dent adhesion to ICAM-1 (Supplementary Figure 4a) and
Fibronectin (Supplementary Figure 4b). p66Shc reversed
moreover the abnormally elevated CLL cell migration
toward CXCL12/CCL21 (Supplementary Figure 4c and d).
Hence, the p66Shc expression defect in CLL cells impinges
on their responses to these chemokines at least in part by
modulating the levels of the respective surface receptors
through recycling.
p66Shc promotes the accumulation of internalized
and β-arrestin-bound CXCR4/CCR7 in Rab5+
endosomes
To track internalized CXCR4/CCR7, the MEC transfectants
were stimulated with CXCL12/CCL21 to induce receptor
internalization, then co-stained with antibodies to the
respective receptors and for markers of early (Rab5) or
recycling (Rab11) endosomes [11, 17]. As expected [11, 17,
18], both receptors colocalized to a significant extent with
Rab11 (Supplementary Figure 5) and partially with Rab5
(Fig. 2a) in the control transfectant. Forced p66Shc
expression strongly enhanced the colocalization of recy-
cling CXCR4/CCR7 with Rab5 (Fig. 2a), whereas reducing
their colocalization with Rab11 (Supplementary Figure 5).
Interestingly, CXCL12/CCL21 readily triggered an asso-
ciation of Rab5 with CXCR4/CCR7 in the control trans-
fectant, which was lost at a later time of stimulation, as
assessed by immunoprecipitation (Fig. 3a). Conversely, the
chemokine-dependent interaction of both receptors with
Rab5 was sustained in the presence of p66Shc (Fig. 3a).
Hence, internalized CXCR4/CCR7 rapidly transit through
Rab5+ endosomes to undergo recycling in MEC cells but
accumulate in Rab5+ endosomes in the presence of p66Shc,
accounting for their impaired recycling.
GPCR internalization requires β-arrestin recruitment to
serine-phosphorylated residues [14, 15], which must be
dephosphorylated for β-arrestin release and receptor recy-
cling [21]. Imaging CXCR4/CCR7 in ctr MEC cells showed
a strong but transient colocalization of both receptors with
β-arrestin (Fig. 2b) consistent with their recycling to the
plasma membrane (Fig. 1a), as opposed to the sustained
colocalization at later times in p66Shc-expressing MEC
cells (Fig. 2b). Moreover, the chemokine-triggered inter-
action of CXCR4/CCR7 with β-arrestin, as well as Rab5
was found to be long-lasting in p66 cells when compared
with ctr cells (Fig. 3a) indicating that, in the presence of
p66Shc, CXCR4/CCR7 internalized in response to ligand
binding accumulate in association with β-arrestin in Rab5+
vesicles and are therefore unable to transit to Rab11+
endosomes for recycling.
Both Rab5 and β-arrestin co-precipitated with p66Shc
following stimulation with CXCL12/CCL21, forming a
long-lasting complex (Fig. 3b). Together with the ability of
CXCR4/CCR7 to interact with p66Shc in a ligand-
independent manner (Fig. 3b), this suggests that p66Shc
may stabilize their association with β-arrestin at early
endosomes, preventing their traffic along their recycling
route.
To understand whether the p66Shc defect in CLL cells,
which correlates with enhanced CXCR4/CCR7 recycling,
leads to alterations in the dynamics of their interaction with
Rab5 or β-arrestin similar to the MEC transfectants, we
compared the colocalization of CXCR4/CCR7 with Rab5
and β-arrestin in B cells purified from healthy donors (HDs)
and M-CLL or U-CLL patients at a late time point of sti-
mulation with the respective chemokines. A significant
CXCR4/CCR7 colocalization with both Rab5 and β-arrestin
was observed in B cells from healthy donors (Figs. 4a, b).
This was markedly lower in CLL cells, especially of the U-
CLL subgroup (Figs. 4a, b). p66Shc reconstitution in CLL
cells largely restored CXCR4/CCR7 colocalization with
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Fig. 2 p66Shc expression enhances CXCR4/CCR7 colocalization with
Rab5 and β-arrestin in MEC B cells. a Immunofluorescence analysis of
Rab5 (red) and either CXCR4 (green, left) or CCR7 (green, right) in
ctr and p66 MEC B cells incubated with 100 ng/ml of CXCL12/
CCL21 at 37 °C for 40 min, fixed and permeabilized. Representative
median optical sections are shown. The quantification using Mander’s
coefficient of the weighted colocalization of CXCR4 (left) or CCR7
(right) with Rab5 in individual medial confocal sections is shown
below the corresponding images (n= 3). b Immunofluorescence ana-
lysis of β-arrestin (red) and either CXCR4 (green, left) or CCR7
(green, right) in ctr and p66 MEC B cells incubated with 100 ng/ml of
CXCL12/CCL21 at 37 °C for either 10 or 40 min, fixed and permea-
bilized. Representative median optical sections are shown. The
quantification using Mander’s coefficient of the weighted colocaliza-
tion of CXCR4 (left) or CCR7 (right) with β-arrestin in individual
medial confocal sections is shown below the corresponding images (n
= 3). Representative median optical sections are shown. Size bar, 5
µm, mean±SD; ≥ 20 cells per marker. Error bars, SD. Student’s t-test
(unpaired). ***p<0.001
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Rab5 and β-arrestin (Fig. 4c). Hence, p66Shc deficiency
leads to a reduction in CXCR4/CCR7 accumulation in early
endosomes in CLL cells, accounting for their faster
recycling.
p66Shc inhibits CXCR4 and CCR7 recycling by
impairing their PP2B-dependent dephosphorylation
GPCR traffic from Rab5+ endosomes requires their
dephosphorylation-dependent β-arrestin release [21]. As
p66Shc inhibits CXCR4/CCR7 recycling by promoting
their accumulation in Rab5+ endosomes in association with
β-arrestin, we hypothesized that dephosphorylation of these
receptors might be impaired in the presence of p66Shc.
CXCR4/CCR7 were immunoprecipitated from the MEC
transfectants stimulated with the respective ligands at two
different time points. Serine phosphorylation of both
receptors was found to increase above basal levels in both
ctr and p66Shc-expressing cells early after stimulation (Fig.
5a). CXCR4 phosphorylation was found to depend on the
activity of both G protein-coupled receptor kinases (GRKs)
and protein kinase C (PKC), but not protein kinase A
(PKA), whereas CCR7 phosphorylation requires only
GRKs, as demonstrated by pre-treating MEC cells with the
non-selective GRK family inhibitor 4-amino-5-(bromo-
methyl)-2-methylpyrimidine hydrobromide [22], or the non-
selective PKC family inhibitor bisindolylmaleimide-1-
hydrochloride [23], or the PKA inhibitor H89 [24] (Sup-
plementary Figure 6a). Interestingly, although CXCR4/
CCR7 phosphorylation decreased at longer times in ctr
cells, consistent with their re-exposure at the plasma
membrane, it remained almost unchanged in p66Shc-
expressing cells (Fig. 5a). This was confirmed for CXCR4
by flow cytometric analysis using an anti-phosphoserine-
339 antibody (Supplementary Figure 7a). Consistent with
the results obtained on the MEC transfectants, CXCR4 was
transiently phosphorylated in response to CXCL12 in CLL
cells as opposed to the sustained phosphorylation in primary
Fig. 3 p66Shc stabilizes the
interaction of CXCR4/CCR7
with Rab5 and β-arrestin in
MEC B cells. a Immunoblot
analysis with anti-β-arrestin and
anti-Rab5 antibodies of CXCR4-
specific (left) and CCR7-specific
(right) immunoprecipitates from
lysates of ctr and p66 MEC B
cells, either unstimulated or
activated with either 500 ng/ml
CXCL12 or 1 µg/ml CCL21.
The stripped filters were repro-
bed with anti-CXCR4 or anti-
CCR7 antibodies. The quantifi-
cation of the relative amount of
β-arrestin and Rab5 is indicated
below the respective immuno-
blots. b Immunoblot analysis
with anti-β-arrestin, -Rab5,
-CXCR4 and -CCR7 antibodies
of CH2-specific immunopreci-
pitates from lysates of p66 MEC
B cells, either unstimulated or
activated with either 500 ng/ml
CXCL12 or 1 µg/ml CCL21.
The stripped filters were repro-
bed with anti-Shc antibodies.
The quantification of the relative
amount of Rab5 and β-arrestin
co-immunoprecipitated with
p66Shc is shown on the right.
The migration of molecular
mass markers is indicated. The
immunoblots shown in the fig-
ure are representative of three
independent experiments. Error
bars, SD. Student’s t-test
(unpaired). **p<0.01; *p<0.05
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Fig. 4 p66Shc reconstitution in CLL B cells enhances CXCR4/CCR7
colocalization with Rab5 and β-arrestin. a, b Immunofluorescence ana-
lysis of Rab5 (green) a or β-arrestin (green) b, and either CXCR4 (red) or
CCR7 (red) in B cells purified from healthy donors (HD, n= 15) and
from M-CLL (n= 17) or U-CLL (n= 15) patients, incubated with 100
ng/ml of CXCL12/CCL21 at 37 °C for 40min, fixed and permeabilized.
Size bar, 5 µm. The quantification using Mander’s coefficient of the
weighted colocalization of CXCR4 (left) or CCR7 (right) with Rab5 and
β-arrestin in individual medial confocal sections is shown below the
corresponding images. c Quantification using Mander’s coefficient of the
weighted colocalization of CXCR4 (left) or CCR7 (right) with Rab5 and
β-arrestin in individual medial confocal sections of purified CLL B cells
(n= 13), nucleofected with either empty vector (ctr) or an expression
construct encoding p66Shc (p66), incubated with 100 ng/ml of CXCL12/
CCL21 at 37 °C for 40min, fixed and permeabilized (mean±SD; ≥ 30
cells per marker per donor or CLL patient). Representative median optical
sections are shown. Size bar, 5 µm. Error bars, SD. Mann–Whitney rank
sum test (unpaired). ***p<0.001
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B cells from healthy donors (Supplementary Figure 7b).
This abnormality was reversed by forced p66Shc expression
(Supplementary Figure 7c). Hence, p66Shc prolongs the
interaction of CXCR4/CCR7 with β-arrestin and hence their
residency in early endosomes by inhibiting their
dephosphorylation.
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The phosphoserine phosphatase responsible for CXCR4/
CCR7 dephosphorylation is unknown. We reasoned that
pharmacological inhibitors that would phenocopy the
effects of p66Shc expression would provide clues to the
identity of this phosphatase. CXCR4/CCR7 recycling was
analyzed in ctr MEC cells pretreated with inhibitors of
phosphatases known to be implicated in recycling of other
GPCRs. We used 10 nM okadaic acid to inhibit PP2A [25],
100 nM okadaic acid to inhibit PP1 and PP2A [26], and 1
µM CsA or FK506 to inhibit PP2B (also known as calci-
neurin) [27]. PP1 and PP2A inhibitors did not affect
CXCR4/CCR7 recycling. Conversely, a profound inhibition
was observed in the presence of CsA or FK506 (Fig. 5b),
implicating PP2B in CXCR4 and CCR7 dephosphorylation.
This notion was supported by the prolonged phosphoryla-
tion of CXCR4/CCR7 observed in ctr MEC cells pretreated
with CsA or FK506 and stimulated with the respective
ligands (Supplementary Figure 6b and c). These results
were recapitulated by knocking-down PP2BCA, the cata-
lytic subunit of PP2B, in ctr MEC cells, which resulted in a
profound inhibition of CXCR4/CCR7 recycling (Fig. 5c)
and their prolonged phosphorylation in response to the
respective ligands (Fig. 5d).
Interestingly, PP2B was found to interact with both
CXCR4 and CCR7 in the MEC transfectants. This inter-
action was enhanced in response to the respective chemo-
kines early after stimulation in both transfectants (Fig. 5e).
Although the amount of PP2B co-immunoprecipitated with
CXCR4/CCR7 decreased at a longer stimulation time in ctr
MEC cells, concomitant with their dephosphorylation (Fig.
5a), this did not occur in p66-expressing cells (Fig. 5e).
These data implicate PP2B in CXCR4/CCR7 depho-
sphorylation and suggest that PP2B is subsequently released
to allow their recycling to the plasma membrane.
p66Shc inhibits CXCR4/CCR7-dependent PP2B
activation by suppressing Ca2+ flux
To elucidate the mechanism underlying the inhibition of
PP2B-dependent CXCR4/CCR7 dephosphorylation by
p66Shc we tested the expression and activity of PP2B in the
MEC transfectants. PP2B expression was not affected by
p66Shc (Fig. 6a). Based on the Ca2+ dependence of PP2B
[24] and the ability of p66Shc to attenuate CXCR4/
CXCR5 signaling [20], we analyzed CXCL12/CCL21-
induced [Ca2+]i mobilization. Chemokine stimulation of ctr
MEC cells triggered a [Ca2+]i elevation, which was strongly
impaired in the p66Shc-expressing transfectant (Fig. 6a and
Supplementary Figure 8a), suggesting that p66Shc may
inhibit PP2B activation by blocking CXCR4/CCR7-
dependent Ca2+ mobilization. To assess this possibility, we
transiently transfected ctr and p66Shc-expressing MEC
cells with a reporter encoding green fluorescent protein
(GFP)-tagged nuclear factor of activated T cells (NFAT), a
transcription factor that requires PP2B-mediated depho-
sphorylation for nuclear translocation [28], and scored the
number of cells harboring nuclear NFAT-GFP following
CXCL12 or CCL21 stimulation. Both chemokines triggered
nuclear translocation of NFAT-GFP in ctr MEC cells,
which was impaired in the p66Shc-expressing transfectant
(Fig. 6c). Of note, we did not observe any significant effect
of p66Shc overexpression on chemokine-mediated apopto-
sis, as assessed by AnnexinV/propidium iodide staining,
ruling out the possibility that p66Shc could impair cell
viability, at least early after chemokine stimulation (Sup-
plementary Figure 9). Hence, p66Shc inhibits PP2B acti-
vation by impairing chemokine-dependent [Ca2+]i
mobilization, supporting the notion that the sustained
phosphorylation of CXCR4/CCR7 in p66Shc-expressing
cells results from defective PP2B activation.
Consistent with these results, B cells from CLL patients
displayed an enhancement in CXCL12- and CCL21-
dependent [Ca2+]i mobilization (Fig. 6e and Supplemen-
tary Figure 8b) and NFAT-GFP nuclear translocation (Fig.
Fig. 5 p66Shc inhibits PP2B-dependent dephosphorylation of CXCR4
and CCR7. a Immunoblot analysis with anti-phospho-CXCR4 or anti-
phosphoserine antibodies of either CXCR4-specific (left) or CCR7-
specific (right) immunoprecipitates from lysates of ctr and p66 MEC B
cells, either unstimulated or activated for 5 and 30 min with either 500
ng/ml CXCL12 or 1 µg/ml CCL21. The stripped filters were reprobed
with anti-CXCR4 or anti-CCR7 antibodies. b Flow cytometric analysis
of CXCR4/CCR7 recycling in ctr MEC B cells incubated for 30 min at
37 °C with DMSO, 10 and 100 nM okadaic acid (OA), 1 µM CsA, or
1 µM FK506. Data are presented as % of internalized receptors that
have recycled to the cell surface at the indicated times and refer to
duplicate samples from three independent experiments. c Flow cyto-
metric analysis of CXCR4/CCR7 recycling in ctr MEC B cells tran-
siently transfected with 1 µg of either ctr siRNA (RLUC) or siRNA for
PP2BCA (residual PP2BCA: 20%). A construct encoding GFP under
the control of a constitutive promoter was included in each transfection
as a control. Analyses were carried out at 48 h post-transfection, gating
on GFP+ live cells. Data are presented as % of internalized receptors
that have recycled to the cell surface at the indicated times and refer to
duplicate samples from three independent experiments. d Immunoblot
analysis with anti-phospho-CXCR4 (left) or anti-phosphoserine anti-
bodies (right) of lysates (left) or CCR7-specific immunoprecipitates
from lysates (right) of ctr MEC B cells, transiently transfected with 1
µg of either ctr siRNA (RLUC) or siRNA for PP2BCA (residual
PP2BCA: 20%) and either unstimulated or activated for 5 and 30 min
with either 500 ng/ml CXCL12 or 1 µg/ml CCL21. The stripped filters
were reprobed with anti-CXCR4 or anti-CCR7 antibodies. e Immu-
noblot analysis with anti-PP2B antibodies of either CXCR4-specific
(left) or CCR7-specific (right) immunoprecipitates from lysates of ctr
and p66 MEC B cells, either unstimulated or activated for 5 and 30
min with either 500 ng/ml CXCL12 or 1 µg/ml CCL21. The stripped
filters were reprobed with anti-CXCR4 or anti-CCR7 antibodies. The
quantification of the relative protein amount is indicated below the
respective immunoblots. The immunoblots shown in the figure are
representative of three independent experiments. Error bars, SD. Stu-
dent’s t-test (unpaired). ***p<0.001; **p<0.01; *p<0.05
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6f) compared with healthy donor B cells while expressing
comparable PP2B levels (Fig. 6d). These data support the
inhibitory role of p66Shc in PP2B-mediated CXCR4/CCR7
dephosphorylation and provide a mechanism for the recy-
cling defect in CLL cells.
Ibrutinib normalizes CXCR4 and CCR7 recycling by
enhancing p66Shc expression
Treatment of CLL patients with ibrutinib, a Btk inhibitor
used in clinical trials alone or in combination with con-
ventional chemotherapeutic drugs [29, 30], results in mas-
sive leukemic cell mobilization from lymph nodes
paralleled by a transient lymphocytosis [31]. We found that
ibrutinib corrects the imbalance between homing and egress
receptors in CLL cells in vitro and in vivo by modulating
CCR7 and S1PR1 expression [11] (Supplementary Figure
10), which is expected to promote leukemic cell exit from
the pro-survival stromal niche [31–34].
As p66Shc modulates CCR7 and S1PR1 expression [13],
we hypothesized that these effects of ibrutinib could be
accounted for by enhanced p66Shc expression. Ibrutinib
treatment of CLL cells resulted indeed in a robust dose-
dependent increase in p66Shc expression, as measured by
quantitative reverse transcriptase-PCR (Fig. 7a and Sup-
plementary Figure 11a). A significant in vivo upregulation
of p66Shc expression was also observed in CLL cells from
patients administered daily for 4 months with ibrutinib (Fig.
7a).
Consistent with the inhibitory effects of p66Shc on
CXCR4/CCR7 recycling, ibrutinib-treated CLL cells dis-
played a reduction in CXCR4/CCR7 recycling (Fig. 7b) and
their subcellular distribution became largely intracellular
(Fig. 7c) resulting in a dose-dependent decrease in the ratio
of surface-to-total receptors (Fig. 7d and Supplementary
Figure 11b-e). Ibrutinib treatment restored moreover
CXCR4/CCR7 colocalization of with Rab5 and β-arrestin in
CLL cells (Fig. 7e). These results further support a role for
p66Shc as a central regulator of CXCR4/CCR7 transit
throughout the recycling route.
Discussion
Beside gene transcription [13], receptor recycling is an
important determinant in controlling the levels of surface
chemokine receptors and downstream responses in CLL
[11]. Here we implicate the p66Shc defect harbored by CLL
cells [19] in the abnormal recycling on which elevated
surface CXCR4/CCR7 expression largely depends. We
show indeed that p66Shc negatively regulates CXCR4/
CCR7 recycling by inhibiting the Ca2+-dependent activa-
tion of the phosphatase PP2B that we identify as responsible
for their dephosphorylation. This results in the accumula-
tion of the internalized β-arrestin-bound receptors in Rab5+
endosomes and hence their failure to transit to recycling
endosomes. We provide moreover novel insights into the
molecular mechanisms that underlie the therapeutic effects
of ibrutinib in CLL by showing that it targets homing
receptor recycling, normalizing the surface levels and sub-
cellular distribution of CXCR4/CCR7 in CLL cells by
upregulating p66Shc expression.
Chemokine-dependent signaling is rapidly modulated
post-translationally by receptor internalization and recy-
cling. The mechanism regulating CXCR4 and CCR7 recy-
cling has been partly elucidated in cell types other than B-
lymphocytes, where it has been shown to require β-arrestin
binding to the serine-phosphorylated cytosolic tail, inter-
nalization and transport to Rab5+ endosomes [16–18, 35–
40]. Similar to other GPCRs [21, 41], β-arrestin release
through dephosphorylation is required for chemokine
receptor transit from early-to-recycling endosomes [16, 17,
39]. Our results show that, while internalized CXCR4 is
preferentially targeted to late endosomes and CCR7 to
recycling endosomes in other cell types [16, 17, 42], these
receptors appear to follow the same route in B cells, both
undergoing recycling through a pathway involving
dephosphorylation-dependent β-arrestin release at Rab5-
positive early endosomes. We have identified PP2B as the
phosphatase shared by CXCR4 and CCR7, with which it
interacts, for this step.
Fig. 6 p66Shc inhibits CXCR4/CCR7-dependent PP2B activation. a,
d Immunoblot analysis with anti-PP2B antibodies of postnuclear
supernatants from ctr and p66 MEC B cells a or from purified healthy
donor (HD), M-CLL or U-CLL B cells d. The stripped filters were
reprobed with anti-actin antibodies. b Fluorimetric analysis of [Ca2+]i
in ctr and p66 MEC B cells stimulated with 100 ng/ml of CXCL12/
CCL21. The arrow indicates the time of addition of chemokines, 1 mM
EGTA and 1 mM CaCl2, respectively. The total levels of store-
associated Ca2+, as measured after cell solubilization by digitonin
treatment in the presence of EGTA, were similar in all cell lines.
Representative experiments are shown (n= 3). c Confocal microscopy
of ctr and p66 MEC B cells transiently transfected with a GFP-NFAT
expression construct, either unstimulated (ns) or stimulated with 100
ng/ml CXCL12 or CCL21 for 1 h or with 500 ng/ml A23187 (A23) for
20 min. The percentage of cells displaying nuclear GFP-NFAT was
calculated by analyzing at least 100 cells per sample (n= 3). e
Fluorimetric analysis of [Ca2+]i in purified HD or CLL B cells sti-
mulated with 100 ng/ml CXCL12 or CCL21. The total levels of store-
associated Ca2+ were similar in all samples (data not shown). Repre-
sentative experiments are shown (HD= 11, CLL= 10). f Confocal
microscopy of purified HD or CLL B cells transiently transfected with
a GFP-NFAT expression construct, either unstimulated (ns) or sti-
mulated with 100 ng/ml of CXCL12 or CCL21 for 1 h or with 500 ng/
ml A23 for 20 min. The percentage of cells displaying nuclear GFP-
NFAT was calculated by analyzing at least 100 cells per sample (HD
= 5, M-CLL= 6). Error bars, SD. Student’s t-test (unpaired).
**p<0.01; *p<0.05
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Fig. 7 Ibrutinib promotes p66Shc expression in CLL cells and nor-
malizes CXCR4 and CCR7 recycling. a Bottom, quantitative RT-PCR
analysis of p66Shc mRNA either on purified peripheral B cells from
five CLL patients with lymphadenopathy, before (pre) and after (post)
4-month in vivo ibrutinib treatment, or on B cells from 23 CLL
patients treated in vitro with either DMSO or 10 µM ibrutinib for 48 h.
The relative gene transcript abundance was determined on triplicate
samples using the ddCt method (fold change in samples post- versus
pre-treatment). Top, immunoblot analysis with anti-Shc antibodies of
CLL cells treated or untreated with ibrutinib, as above. The stripped
filter was reprobed with anti-actin antibodies. b Flow cytometric
analysis of CXCR4/CCR7 recycling in purified CLL B cells treated
in vitro with either DMSO or 10 µM ibrutinib for 48 h. Data are pre-
sented as % of internalized receptors that have recycled to the cell
surface and refer to duplicate samples (n= 4). c Flow cytometric
analysis of CXCR4 or CCR7 on purified CLL B cells treated in vitro
with either DMSO or 10 µM ibrutinib for 48 h, either non-
permeabilized (n-perm) or permeabilized (perm). d Ratio of surface-
to-total MFI of CXCR4 and CCR7 from CLL B cells treated in vitro
with either DMSO or 10 µM ibrutinib for 48 h. Data are expressed as
ratio of MFI in non-permeabilized cells (surface) to permeabilized
(total) cells. e Quantification using Mander’s coefficient of the
weighted colocalization of CXCR4 or CCR7 with Rab5 and β-arrestin
in individual medial confocal sections of purified CLL B cells (n= 5)
treated in vitro with either DMSO or 10 µM ibrutinib for 48 h, incu-
bated with 100 ng/ml of CXCL12/CCL21 at 37 °C for 40 min, fixed
and permeabilized. Representative median optical sections are shown
on the right (mean±SD; ≥ 20 cells per marker). Size bar, 5 µm. Error
bars, SD. Mann–Whitney rank sum test (unpaired). ***p<0.001;
**p<0.01; *p<0.05
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Several GPCRs colocalize with Rab5 and rely on its
GTPase activity for their internalization and traffic [43]. A
role for membrane receptors in regulating their own traffic
through recruitment and activation of components of the
Rab-based traffic machinery has been demonstrated in very
few instances, which include the polymeric IgA receptor
and the GPCR AT1AR, which interact with Rab3b and
Rab5, respectively [44, 45]. Other GPCRs are indirectly
coupled to Rab5 through interactors that are beginning to be
identified. One example is CXCR4, which has been recently
shown to require the protein missing-in-metastasis for
ligand-dependent internalization and Rab5 binding in HeLa
cells [46]. Our data demonstrate the existence of a multi-
molecular complex, which includes CXCR4/CCR7, β-
arrestin, Rab5 and PP2B and is stabilized by p66Shc.
Whether Rab5 interacts directly or indirectly with these
receptors in B cells, which are the reciprocal interactions
among the components of the complex, and how p66Shc
prolongs its half-life are questions that remain to be
clarified.
p66Shc inhibits CXCR4- and CXCR5-dependent sig-
naling by interacting with these receptors to promote the
assembly of an inhibitory complex containing the phos-
phatases SHP-1 and SHIP-1, which results in impaired
spleen tyrosine kinase (Syk) and Btk phosphorylation [20].
Both kinases contribute to BCR-dependent PLC-γ2 activa-
tion, which in turn initiates inositol-1,4,5-tris-phosphate-
dependent [Ca2+]i mobilization [47]. Here we show a major
defect of chemokine-dependent [Ca2+]i mobilization in
p66Shc-expressing B cells, which could be accounted for
by impaired Syk and Btk phosphorylation. This defect is
likely to underlie the defect in PP2B activation, which is
dependent on Ca2+-calmodulin, resulting in the failure of
CXCR4/CCR7 to become dephosphorylated and hence in
their endosomal accumulation. The fact that p66Shc mod-
ulates CXCR5 signaling [20] raises the possibility that the
p66Shc-dependent and PP2B-mediated regulation of endo-
some recycling may extend to this homing receptor, which
controls local B-cell traffic in SLOs and, similar to CCR7
and CXCR4, is overexpressed at the surface of CLL B cells
[48].
Emerging evidence indicates that surface receptors con-
tinue signaling at endosomes following ligand-dependent
internalization [49]. This may compartmentalize signaling
to specific subcellular localizations, as shown for endoso-
mal β-2 adrenergic receptors [50]. The finding that serine-
phosphorylated CXCR4/CCR7 are found at Rab5+ endo-
somes in association with β-arrestin and PP2B suggests that
PP2B is activated locally to dephosphorylate the receptors,
allowing their transit to recycling endosomes. This could be
achieved through [Ca2+]i mobilization by endosomal
CXCR4/CCR7. The tight packing of membrane compart-
ments within the scant B-cell cytosol is expected to allow
[Ca2+]i mobilization close to endosomes carrying signaling
CXCR4/CCR7 from neighboring endoplasmic reticulum
and/or mitochondria. This process would be impaired in the
presence of p66Shc due to its ability to interact with and
inhibit Ca2+ signaling by endosomal CXCR4/CCR7.
The finding that p66Shc limits CXCR4/CCR7 recycling,
together with its ability to modulate CCR7 and S1PR1
expression [13] and CXCR4 signaling [11], underscores the
importance of the p66Shc defect in CLL cell homing to
and accumulation in the protective stromal niche. This is
supported by the rescue of p66Shc expression in ibrutinib-
treated CLL cells, with the resulting inhibition of
CXCR4/CCR7 recycling and decrease in surface expres-
sion. These data provide a partial explanation for the
molecular mechanisms that underlie the massive efflux of
leukemic cells from lymphoid tissues and the consequent
transient lymphocytosis in ibrutinib-treated patients [34,
51]. We have reported that p66Shc expression is regulated
by the transcription factor STAT4, which is profoundly
reduced in CLL cells [52], suggesting that ibrutinib may
promote p66Shc expression by increasing the levels of
STAT4.
In conclusion, we have identified p66Shc as a negative
regulator of CXCR4/CCR7 recycling acting at the early-to-
recycling endosome transit step by preventing their Ca2
+-dependent dephosphorylation by receptor-associated
PP2B. We have moreover implicated the p66Shc defect in
CLL cells in the recycling abnormalities of CXCR4 and
CCR7, which contribute to their robust responses to the
respective pro-survival stromal ligands. Finally, we provide
new insights into the mechanisms underlying the ther-
apeutic effects of ibrutinib in CLL.
Materials and methods
Patients and healthy donors
Peripheral blood (PB) samples were collected from 78
patients satisfying standard morphologic and immunophe-
notypic criteria for CLL. Mutational IGHV status was
assessed as reported [53], with a sequence homology ≤98%
with the germ-line counterpart considered mutated. B cells
from 42 buffy coats were used as adult healthy population
controls. At collection, patients had never received treat-
ment. For five patients, PB samples were collected before
and after a 4-month Ibrutinib treatment with fixed 420 mg
daily dose, administered orally on continuous schedule.
B cells were purified by negative selection using
RosetteSep B-cell enrichment Cocktail (StemCell Tech-
nologies, Vancouver, Canada) followed by density gradient
centrifugation on Lympholite (Cedarlane Laboratories, The
Netherlands).
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Cell lines, plasmids, transfections and reagents
Stable control and p66Shc-expressing transfectants gener-
ated using the CLL-derived B-cell line MEC [54] were
previously described [13, 20]. CLL cells were transiently
co-transfected with 1 μg GFP reporter per sample and 5 μg
pcDNA3 or p66Shc-encoding pcDNA3 using the Human
B-cell Nucleofector Kit (Amaxa Biosystems, Cologne,
Germany). Transfection efficiency was ≥40%, as assessed
by flow cytometry of GFP+ cells, and cell viability 48 h
post-transfection was 40–60%. Human PP2BCA-specific
endoribonuclease-prepared small interfering RNAs (esiR-
NAs) (Mission PPP3CA esiRNA, #EHU017161) and
unrelated control Renilla luciferase (RLUC) esiRNA (Mis-
sion RLUC esiRNA, #EHURLUC) (Sigma-Aldrich, Milan,
Italy) were transfected by electroporation and assays carried
out after 48 h. For recycling experiments, cells were tran-
siently co-transfected with esiRNAs and pmaxGFP control
(Amaxa Biosystems). p66Shc was immunoprecipitated
using a rabbit polyclonal antiserum raised against a glu-
tathione S-transferase fusion protein that includes the N-
terminal CH2 domain of p66Shc, allowing for discrimina-
tion from the shorter ShcA isoforms. Commercial anti-
bodies used in this study are listed in Supplementary Table
1. Human and mouse CXCL12 and CCL21, S1P, CsA,
FK506, okadaic acid, bisindolylmaleimide-1-hydrochloride
and fibronectin were purchased from Sigma-Aldrich; ibru-
tinib from Selleckchem (Munich, Germany); 4-amino-5-
(bromomethyl)-2-methylpyrimidine hydrobromide from
Santa Cruz (Santa Cruz, CA); H89 from MerckMillipore
(Darmstadt, Germany). rhICAM-1/Fc was purchased from
R&D Systems. The chemiluminescence detection kit was
from Pierce (Rockford, IL).
Mice
p66Shc-/-/129 and wild-type 129 mice were previously
described [55]. Non-randomized non-blinded experiments
were carried out on splenic B cells negatively purified by
immunomagnetic sorting from age- and sex-matched 2- to
9-month-old mice using the Dynabeads Mouse CD43
Negative Isolation Kit (Invitrogen) (>85% purity).
Activations, immunoprecipitations, and
immunoblots
Cells were starved for 2 h in Roswell Park Memorial
Institute (RPMI)-1% bovine serum albumin (BSA) and
activated at 37 °C with 500 ng/ml CXCL12 or 1 µg/ml
CCL21 (Sigma-Aldrich). For immunoblots, cells were lysed
in 1% Triton X-100, 20 mM Tris–HCl (pH 8), 150 mM
NaCl and protease inhibitors (Invitrogen). Postnuclear
supernatants were processed for immunoblot as described
[56] or immunoprecipitated (2.5–5× 107 cells per sample)
using protein A-Sepharose (GE Healthcare, Little Chalfont,
UK) in the presence of the indicated antibody or unrelated
immunoglobulin (negative control).
RNA purification and reverse transcriptase-PCR (RT-
PCR)
RNA was extracted and retrotranscribed as described [19].
Real-time PCR was performed in triplicate on 96-well
optical PCR plates (Sarstedt AG, Nümbrecht, Germany)
using SSo FastTM EvaGreenR SuperMix and a CFX96 Real-
Time system (Bio-Rad Laboratories, Waltham, MA).
Results were processed and analyzed as described [11].
Transcript levels were normalized to HPRT1. Primers used
for amplification are listed in Supplementary Table 2.
Analysis of receptor recycling, cell adhesion,
chemotaxis, and calcium flux
Flow cytometry was carried out using a Guava Easy Cyte
(Millipore) cytometer. Analysis of surface CXCR4/CCR7
was carried out using fluorochrome-conjugated antibodies
or isotype controls. To quantitate the ratio of surface-to-total
CXCR4/CCR7, cells were fixed and permeabilized using
the Cytofix/Cytoperm plus kit (BD), which does not cause
any significant difference in surface CXCR4/CCR7 staining
(Supplementary Figure 12). CXCR4/CCR7 recycling fol-
lowing antibody-dependent downregulation was quantitated
by flow cytometry as described [57]. Briefly, cells were
incubated for 30 min on ice with receptor-specific Abs,
washed, shifted to 37 °C for 40 min, then subjected to acid
stripping (time 0), and incubated for the indicated times at
37 °C. Receptor:Ab complexes that had recycled to the cell
surface were measured by labeling with fluorochrome-
conjugated secondary antibodies. Before S1PR1 staining,
cells were resuspended in serum-free medium, 0.5% fatty
acid-free BSA (Sigma-Aldrich) and incubated for 30 min at
37 °C to allow recycling of intracellular receptors. Adhesion
assays on rhICAM-1/Fc-coated (R&D Systems) or
fibronectin-coated (Sigma-Aldrich) plates in the presence or
absence of 100 ng/ml CXCL12/CCL21 were performed as
described [20]. Chemotaxis assays were carried out using
24-well Transwell chambers with 5-µm pore polycarbonate
membranes (Corning Life Sciences, Schiphol-Rijk, The
Netherlands) as described [56]. Analysis of Ca2+ in Fura-2
loaded cells was carried out in 140 mM NaCl, 5.4 mM KCl,
1 mM MgCl2, 0.2 mM EGTA, 15 mM Hepes, pH 7.4 in the
absence of added Ca2+ as described [58].
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Immunofluorescence microscopy, colocalization
analyses, and NFAT assays
To analyze receptor recycling cells were equilibrated 30 min
at 37 °C in RPMI-1% BSA, incubated with 100 ng/ml
CXCL12/CCL21 at 37 °C for 10 or 40 min, permeabilized
and processed for immunofluorescence microscopy as
described [59]. Images were acquired on a Zeiss LSM700
using a 63X objective as described [59]. The quantitative
colocalization analysis of CXCR4/CCR7 with β-arrestin/
Rab was performed on median optical sections using Ima-
geJ and JACoP plug-in to determine Manders’ coefficient
[60]. For NFAT assays, cells were transiently transfected
with the plasmid pEGFP/NFAT-1D [61] using the Human
B-cell Nucleofector Kit (primary B cells) or a modification
of the DEAE/dextran procedure (MEC cells), as described
[62]. After 24 h, cells were resuspended in RPMI-1% BSA,
stimulated with 100 ng/ml CXCL12/CCL21 at 37 °C for 1 h
or 500 ng/ml A23187 for 20 min, fixed and stained with
anti-GFP antibodies.
Statistical analyses
Mean values, standard deviations and Student’s t-test
(unpaired) were calculated using Microsoft Excel. The
Mann–Whitney rank sum test was used to analyze CLL
samples. A level of p< 0.05 was considered statistically
significant. Sample size, determined on the basis of pre-
vious experience in the laboratory, and replicate number for
each experimental group/condition are indicated in the fig-
ure legends.
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